Natera (NASDAQ:NTRA) PT Raised to $150.00 at Leerink Partners

Natera (NASDAQ:NTRA) had its price objective raised by Leerink Partners from $140.00 to $150.00 in a research note issued to investors on Thursday morning, Benzinga reports. The brokerage currently has an outperform rating on the medical research company’s stock.

Several other analysts have also weighed in on NTRA. Canaccord Genuity Group upped their target price on Natera from $130.00 to $145.00 and gave the company a “buy” rating in a report on Tuesday, August 27th. StockNews.com lowered Natera from a “hold” rating to a “sell” rating in a research note on Wednesday, August 28th. BTIG Research raised their price target on Natera from $125.00 to $135.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. UBS Group reduced their price objective on Natera from $160.00 to $145.00 and set a “buy” rating on the stock in a research report on Friday, August 9th. Finally, The Goldman Sachs Group lifted their price objective on Natera from $125.00 to $140.00 and gave the stock a “buy” rating in a research report on Wednesday. One equities research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. According to data from MarketBeat, Natera presently has an average rating of “Moderate Buy” and a consensus price target of $124.44.

Natera Stock Performance

NASDAQ NTRA opened at $122.35 on Thursday. The firm has a market cap of $15.02 billion, a P/E ratio of -39.21 and a beta of 1.53. The company has a quick ratio of 4.01, a current ratio of 4.14 and a debt-to-equity ratio of 0.34. The business’s 50-day moving average price is $123.15 and its 200 day moving average price is $110.16. Natera has a 52-week low of $36.90 and a 52-week high of $133.54.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Thursday, August 8th. The medical research company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.69) by $0.39. The business had revenue of $413.35 million during the quarter, compared to analysts’ expectations of $343.00 million. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The company’s quarterly revenue was up 58.1% compared to the same quarter last year. During the same period last year, the firm earned ($0.97) EPS. On average, equities research analysts expect that Natera will post -1.96 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Steven Leonard Chapman sold 4,523 shares of the business’s stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $130.40, for a total transaction of $589,799.20. Following the completion of the sale, the chief executive officer now directly owns 191,163 shares of the company’s stock, valued at $24,927,655.20. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other news, CEO Steven Leonard Chapman sold 4,523 shares of the stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $130.40, for a total value of $589,799.20. Following the completion of the sale, the chief executive officer now owns 191,163 shares of the company’s stock, valued at $24,927,655.20. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Solomon Moshkevich sold 549 shares of the firm’s stock in a transaction dated Monday, July 22nd. The shares were sold at an average price of $105.16, for a total value of $57,732.84. Following the completion of the transaction, the insider now directly owns 113,637 shares in the company, valued at $11,950,066.92. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 50,765 shares of company stock valued at $6,016,700 over the last quarter. Company insiders own 7.60% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. SG Americas Securities LLC increased its stake in shares of Natera by 1,073.1% in the second quarter. SG Americas Securities LLC now owns 65,730 shares of the medical research company’s stock worth $7,118,000 after buying an additional 60,127 shares during the last quarter. Russell Investments Group Ltd. increased its holdings in shares of Natera by 15.1% in the 1st quarter. Russell Investments Group Ltd. now owns 74,460 shares of the medical research company’s stock valued at $6,810,000 after acquiring an additional 9,781 shares during the last quarter. Natixis acquired a new stake in shares of Natera during the first quarter worth $758,000. Allspring Global Investments Holdings LLC raised its stake in Natera by 19.9% during the first quarter. Allspring Global Investments Holdings LLC now owns 863,406 shares of the medical research company’s stock worth $78,967,000 after acquiring an additional 143,246 shares during the period. Finally, Baader Bank Aktiengesellschaft acquired a new stake in shares of Natera during the 2nd quarter worth approximately $478,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.